Archiv der Pharmazie最新文献

{"title":"Innovative Se-Flutamide Derivatives: Enhanced Activity Toward Androgen Receptor (AR)-Dependent and -Independent Prostate Cancer Cells","authors":"Cristina Morán-Serradilla,&nbsp;Carmen Sanmartín,&nbsp;Asif Raza,&nbsp;Ignacio Encío,&nbsp;Daniel Plano,&nbsp;Arun K. Sharma","doi":"10.1002/ardp.70119","DOIUrl":"10.1002/ardp.70119","url":null,"abstract":"<p>Sixteen novel selenoderivatives of flutamide, which is used for treating androgen receptor (AR)-dependent prostate cancer, were developed. All the Se derivatives displayed promising activity against the NCI-60 human cancer cell line panel, which also includes two AR-independent prostate cancer cell lines, DU-145 and PC-3. Conversely to flutamide, compounds <b>a2</b>, <b>a5</b>, and <b>b4</b> exhibited a potent antiproliferative effect toward AR-dependent LNCaP cells. Several cell death inhibitors were used to determine the underlying regulated cell death processes of <b>a5</b>. Regarding its mechanism of action in these cells, this compound promoted apoptosis by activating both intrinsic and extrinsic apoptotic pathways, without generating reactive oxygen species (ROS). Besides, it induced the G0/G1 cell cycle arrest. Altogether, it could be concluded that this Se-flutamide analog could be a feasible and promising candidate for further development for the treatment of both AR-dependent and -independent prostate cancers.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70119","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structure-Based Design of Chiral Thioureas as Anticholinesterase Inhibitors Using Enantiopure α-Methylbenzylamines: Synthesis, Enzyme Inhibition, and In Silico Studies","authors":"Zafer Bulut,&nbsp;Ayşegül Karaküçük-Iyidoğan,&nbsp;Melike Bilge,&nbsp;Yusuf Sicak,&nbsp;Zeynep Dilan Turgut-Solak,&nbsp;Emine Elçin Oruç-Emre","doi":"10.1002/ardp.70124","DOIUrl":"10.1002/ardp.70124","url":null,"abstract":"<div>\u0000 \u0000 <p>A detailed analysis of the research on the treatment of Alzheimer's disease indicates that selective inhibition of butyrylcholinesterase (BChE) is the most promising strategy for identifying a drug target. According to this perspective, in this study, a new series of potential BChE inhibitors (<b>1a–8a</b> and <b>1b–8b</b>) were designed using a structure-based design approach and synthesized as enantiomer pairs based on the benzyl thiourea attached to a chiral moiety. The in vitro anticholinesterase activity studies against acetylcholinesterase (AChE) and BChE consistently demonstrated that the majority of the designed compounds exhibited selective and potent BChE inhibition. Also, the present results of the study reveal that compound <b>6b</b>, which has a methyl group at the <i>para</i> position of the phenyl ring and has an <i>S</i> configuration, was the most potent compound against BChE with an IC₅₀ value of 1.46 ± 1.99 μM (<i>SI</i> = 8.47). In contrast, the chiral thioureas (<b>8a</b> and <b>8b</b>) bearing a cyclohexyl group demonstrated higher selectivity toward AChE, with SI values of 2.10 and 2.32, respectively. Notably, compounds <b>2a</b> and <b>2b</b> showed dual inhibitory effects with similar potency for AChE and greater potency for BChE, compared to the standard drug galantamine. The molecular docking method, which showed a good correlation with our in vitro anticholinesterase activity results, was used to predict the interactions of all chiral thioureas within the binding pockets of AChE and BChE. Further structural improvement of these molecules in future studies may lead to the emergence of more potent AChE and BChE inhibitors.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Anticancer and COX-2 Inhibitory Activity of Tailored Paracetamol-Alkanesulfonate Conjugates: A Promising Therapeutic Approach","authors":"Asmaa F. Kassem,&nbsp;Marwa M. Mounier,&nbsp;Mostafa I. Abdelglil,&nbsp;Sameh Abdelwahed,&nbsp;Ahmed A. El-Rashedy,&nbsp;Asmaa Saleh,&nbsp;Mahmoud G. A. Saleh,&nbsp;Aladdin M. Srour","doi":"10.1002/ardp.70125","DOIUrl":"10.1002/ardp.70125","url":null,"abstract":"<div>\u0000 \u0000 <p>Innovative paracetamol-alkanesulfonate conjugates (<b>5a–l</b>) were designed and synthesized through a multi-step process starting with acetaminophen. Their dual functionality as anticancer agents and inhibitors of cyclooxygenase-2 (COX-2), created through a multi-step reaction sequence beginning with acetaminophen, was investigated. The anticancer activity was assessed across seven different cancer cell lines: HOS (osteosarcoma), A-549 (lung), MCF-7 (breast), HT-29 (colon), PC3 (prostate), Caco-2 (colorectal), and HCT-116 (colorectal). Among these conjugates, <b>5d</b> showed exceptional activity against the Caco-2 cell line. The tested compounds demonstrated potent COX-2 activity with IC₅₀ values extending from 0.052 to 0.096 µM. Moreover, compounds <b>5d</b>, <b>5h</b>, and <b>5i</b> displayed remarkable COX-2 selectivity, as reflected by their high selectivity indices and substantially weaker COX-1 inhibition compared to celecoxib, the reference drug. These results are further supported by COX-2 overexpression assays in Caco-2 cells, where compound <b>5d</b> significantly downregulated COX-2 protein levels, reinforcing its potential as a safer and selective COX-2 inhibitor. Further investigation into the mechanism of action revealed that compound <b>5d</b> promotes apoptosis by enhancing the expression of the proapoptotic Bax protein while simultaneously reducing levels of antiapoptotic Bcl-2, ultimately leading to increased caspase-3 expression, cell cycle arrest, and apoptosis. To understand the structural basis for this activity, molecular docking and dynamics simulations were conducted, which confirmed that compound <b>5d</b> forms stable interactions within the catalytic pockets of both Bcl-2 and BAX receptors. These findings suggest that compound <b>5d</b> has significant potential as a dual-acting therapeutic agent.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis and Biological Evaluation of Novel 2-(Piperidin-4-yl)-1,2,3,4-tetrahydroisoquinoline and 2-(Piperidin-4-yl)decahydroisoquinoline Antimycotics","authors":"Marie-Christin Hain,&nbsp;Monika Klimt,&nbsp;Franz Bracher,&nbsp;Ulrike Binder,&nbsp;Jürgen Krauß","doi":"10.1002/ardp.70128","DOIUrl":"10.1002/ardp.70128","url":null,"abstract":"<p>Piperidine antimycotics like fenpropidin are well established in agrochemistry. On the other hand, numerous isoquinoline derivatives show remarkable antimycotic effects. Here we present a series of 13 hybrid molecules of both lead structures, which were prepared using reductive amination as key reaction step. Pre-screening against <i>Yarrowia lipolytica</i> resulted in a batch of promising candidates whose antifungal efficacy was further evaluated against clinically relevant species. In these assays, complete growth inhibition was seen for five or six compounds against <i>C. albicans</i> or <i>C. krusei</i>, respectively, and in two against <i>C. glabrata</i>, whereas no antifungal activity was observed against mold isolates, with the exception of <b>6i</b>, which led to complete growth inhibition of aspergilli, and two compounds (<b>6k</b> and <b>6 l</b>) that were able to inhibit <i>Rhizopus arrhizus</i>.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70128","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145306535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting Lung Cancer: Synthesis, Characterization, Enzyme Inhibition, and Antiproliferative Activity of 1H-Benzo[f]chromen-1-One-Thiosemicarbazones Supported by Molecular Docking","authors":"Shahid Raza,&nbsp;Muhammad Islam,&nbsp;Furkan Çakır,&nbsp;Şeyma Ateşoğlu,&nbsp;Fahri Akbaş,&nbsp;Parham Taslimi,&nbsp;İlhami Gülçin,&nbsp;Salman F. Alamery,&nbsp;Abdallah M. Elgorban,&nbsp;Faiqa Noreen,&nbsp;Mazhar Hussain,&nbsp;Zahid Shafiq,&nbsp;Halil Şenol","doi":"10.1002/ardp.70116","DOIUrl":"10.1002/ardp.70116","url":null,"abstract":"<div>\u0000 \u0000 <p>The aim of this study is to design, synthesize, and characterize novel benzo<i>[f]</i>chromene-substituted thiosemicarbazone derivatives as potential anticancer agents, based on the rationale of simultaneously targeting key cancer-related enzymes and signaling pathways to improve therapeutic efficacy against lung cancer. For these purposes, 18 novel thiosemicarbazone derivatives <b>4a–r</b> were synthesized. Among them, compound <b>4p</b> exhibited the most promising anticancer effects against A549 cells, with an IC₅₀ value of 5.11 µM and a selectivity index (SI) of 10.55, surpassing the reference drug sorafenib. Compound <b>4p</b> also demonstrated potent enzyme inhibitory activity, particularly against hCA I (IC₅₀ = 104.26 nM) and hCA II (IC₅₀ = 95.18 nM), outperforming acetazolamide. In anticancer assays, compound <b>4p</b> (SI = 10.55) was about twice as effective as sorafenib (SI = 5.34), and in enzyme inhibition, it showed ~1.5-fold greater potency than acetazolamide. Molecular docking studies show strong binding interactions of <b>4p</b> with hCA I, hCA II, and BRAF, with favorable docking scores and stable protein–ligand complexes confirmed by 100-ns and 250-ns triplicate random seed MD simulations. Additionally, pharmacokinetic predictions indicated excellent drug-like properties for <b>4p</b>, including high permeability, oral absorption, and adherence to Lipinski's rule. These findings highlight compound <b>4p</b> as a promising candidate for an anticancer agent targeting key enzymes involved in lung cancer progression.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145290408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harnessing Fragment Merging and Chain Extension Approaches for Designing Phthalimidoalkyl-Arylidene Thiazolidinedione Hybrids: New Frontiers in Apoptosis-Inducing Cancer Treatment","authors":"Saad Shaaban,&nbsp;Ayman Abo Elmaaty,&nbsp;Tarek A. Yousef,&nbsp;Marwa Sharaky,&nbsp;Mohamed Alaa Mohamed,&nbsp;Mohamed Alaasar,&nbsp;Arwa Omar Al Khatib,&nbsp;Amal F. Dawood,&nbsp;Fatema S. Alatawi,&nbsp;Awatif M. E. Omran,&nbsp;Khadra B. Alomari,&nbsp;Ahmed A. Al-Karmalawy","doi":"10.1002/ardp.70118","DOIUrl":"10.1002/ardp.70118","url":null,"abstract":"<div>\u0000 \u0000 <p>A series of novel phthalimidoalkyl-arylidene thiazolidinedione hybrids (<b>10a–e</b> and <b>11a–e</b>) were designed and synthesized by the combination of the bioactive phthalimide and thiazolidinedione pharmacophores and connected via an ethyl or propyl linker. Additionally, selenocyanates (<b>12</b> and <b>13</b>) were synthesized via nucleophilic substitution using KSeCN in DMF. The novel phthalimide benzylidene thiazolidinedione hybrids (<b>10a</b>–<b>e</b> and <b>11a</b>–<b>e</b>) and phthalimide selenocyanates (<b>12</b> and <b>13</b>) were examined as apoptotic inducers against 15 cancer cell lines. Compound <b>10e</b> showed the best mean growth inhibition percentage (GI%) of 64.60% compared with the FDA-approved doxorubicin (Dox). Moreover, the synthesized compounds showed higher therapeutic efficacy against the A549 and MDA-MB-468 cell lines compared with HeLa and FaDu cells. Analogs <b>10e</b>, <b>11b</b>, <b>11d</b>, and <b>13</b> displayed the highest cytotoxic potential at the MDA-MB-468 cancer cells with IC₅₀ values of 12.52, 13.16, 12.00, and 14.78 µM, respectively, in comparison to Dox (IC₅₀ = 11.39 µM). Evaluation of the apoptotic and proinflammatory markers after treatment with analog <b>13</b> revealed upregulation of the proapoptotic Caspases 3, 8, and 9 and downregulation of the prosurvival proteins BCL-2, MMP2, and MMP9 by 1.27-, 6.71-, 2.00-, 2.26-, 2.31-, and 2.12-fold change, respectively. Furthermore, analog <b>13</b> showed the most significant downregulation of COX-2 and IL-1β protein expression, showing 2.08- and 2.34-fold changes, respectively. Finally, the molecular docking study against Caspase 6 demonstrated eligible binding affinities of the examined analogs. Overall, this study demonstrated that the synthesized compounds are promising apoptotic inducers and possess great potential as anticancer drugs.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Innovative Pyrazole–Thiazole–Oxadiazole Hybrid Compounds for Targeted EGFR/VEGFR2 Inhibition in Cancer Treatment","authors":"Burak Kuzu,&nbsp;Derya Osmaniye,&nbsp;Abdullah Burak Karaduman,&nbsp;Yusuf Özkay","doi":"10.1002/ardp.70122","DOIUrl":"10.1002/ardp.70122","url":null,"abstract":"<div>\u0000 \u0000 <p>A new series of pyrazole–thiazole–oxadiazole hybrid compounds targeting the EGFR and VEGFR2 enzymes was designed and synthesized using innovative approaches. The compounds were characterized through spectral methods, and their cytotoxic activities were evaluated against the A549 lung and HT-29 colon cancer cell line using the MTT assay. Among them, compounds <b>17i</b> and <b>17m</b> exhibited notable cytotoxicity, with <b>17i</b> demonstrating approximately threefold greater activity compared to the reference drug sorafenib for A549 cells. Flow cytometry analysis revealed that <b>17i</b> induced extensive necrotic cell death, while <b>17m</b> triggered a more targeted and controlled apoptotic mechanism. In vitro enzyme inhibition assays demonstrated that <b>17i</b> inhibited EGFR and VEGFR2 with IC₅₀ values of 0.158 and 0.128 µM, respectively. In contrast, <b>17m</b> exhibited more potent inhibition of EGFR (IC₅₀ = 0.012 µM) and moderate activity against VEGFR2 (IC₅₀ = 0.309 µM). Molecular docking and molecular dynamics simulations further supported the structural stability of the complexes formed by these compounds with their target enzymes, highlighting their potential as effective enzyme inhibitors. Collectively, these findings suggest that pyrazole–thiazole–oxadiazole hybrids represent promising candidates for targeted cancer therapy at the cellular level.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145278489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemometrics-Assisted Spectrophotometric Methods for Determination of Methocarbamol and Paracetamol Along With Two Related Impurities: An Environmental Sustainability Assessment","authors":"Khadiga M. Kelani,&nbsp;Hebatallah M. Essam,&nbsp;Ahmed R. Mohamed,&nbsp;Yasmine F. Bassuoni","doi":"10.1002/ardp.70114","DOIUrl":"https://doi.org/10.1002/ardp.70114","url":null,"abstract":"<div>\u0000 \u0000 <p>Two multivariate calibration models were created for the concurrent estimation of methocarbamol and paracetamol in their co-formulated pharmaceutical dosage form. These methods also enabled the detection of their impurities, <i>p</i>-aminophenol and guaifenesin. The calibration paradigms, based on principal component regression (PCR) and partial least squares (PLS), were employed to assess the drugs and their impurities. The methods demonstrated accurate simultaneous determination of methocarbamol, paracetamol, <i>p</i>-aminophenol, and guaifenesin within the concentration ranges of 20.00–80.00 µg mL⁻¹ for methocarbamol, 20.00–60.00 µg mL⁻¹ for paracetamol, 0.06–4.00 µg mL⁻¹ for <i>p-</i>aminophenol, and 0.08–10.00 µg mL⁻¹ for guaifenesin. The techniques were evaluated in accordance with ICH directions, and the outcomes confirmed the reliability and validity of the developed methods. The suggested approaches were successfully applied to analyze methocarbamol and paracetamol in their combined tablets and to quantify their related impurities. Furthermore, the environmental impact of these techniques was evaluated using a variety of metrics, assessing their greenness and whiteness alongside their practical effectiveness (blueness), with the results highlighting their superior environmental performance. Additionally, the suggested techniques' sustainability was appraised using the recently introduced NQS index, yielding a score of 67.70%, demonstrating strong alignment with sustainable analytical practices.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semi-Synthesis and Biological Evaluation of Phyllanthin Derivatives as Potential Neuroprotective Agents","authors":"Bylapudi Lalitha Kumari,&nbsp;Rahul Kumar,&nbsp;Kakade Aditi Sakharam,&nbsp;Rutuja Damare,&nbsp;Shashi Bala Singh,&nbsp;Gautam Kumar","doi":"10.1002/ardp.70115","DOIUrl":"https://doi.org/10.1002/ardp.70115","url":null,"abstract":"<div>\u0000 \u0000 <p>Oxidative stress is responsible for the functional loss and sensory impairment of neurons, which leads to progressive loss of brain and spinal cord cells and contributes significantly to several neurological disorders, thus eventually resulting in brain atrophy and death. This study involves the isolation of lignans, including phyllanthin, hypophyllanthin, and nirtetraline, from <i>Phyllanthus amarus</i>. Furthermore, the phyllanhtin was semi-synthetically modified to give phyllanthin oxadiazole derivatives and was evaluated for neuroprotective activity in scopolamine-injured neuroblastoma-2a (N2A) cells. The biochemical assay for reactive oxygen generation (ROS) production in N2A cells was carried out using 2′,7′-dichlorodihydrofluorescein diacetate (DCFDA) dye, and the mitochondrial membrane potential (MMP) was determined in N2A cells by using JC-1 dye. Furthermore, the N2A neuronal deaths were evaluated using acridine orange (AO), ethidium bromide (EtBr), and propidium iodide dyes. Among them, nirtetraline, hypophyllanthin, phyllanthin, and compounds <b>21</b> and <b>31</b> showed potential neuroprotective effects in N2A cells against scopolamine-induced neurotoxicity by inhibiting ROS production and improving MMP. Moreover, the synthesized compounds were nontoxic to the N2A cell line. Furthermore, in silico docking studies predicted phyllanthin derivatives <b>21</b> and <b>31</b> exhibit neuroprotective activity by binding to the human NADPH-oxidase 5 enzyme. Thus, compounds <b>21</b> and <b>31</b> can be considered potential neuroprotective leads.</p></div>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145272595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Design, Synthesis, Biological Evaluation, and In Silico Studies of Quinoxaline Derivatives as Potent p38αMAPK Inhibitors”","authors":"","doi":"10.1002/ardp.70120","DOIUrl":"10.1002/ardp.70120","url":null,"abstract":"<p>Anjali, P. Kamboj, O. Alam, et al., “Design, Synthesis, Biological Evaluation, and In Silico Studies of Quinoxaline Derivatives as Potent p38αMAPK Inhibitors,” <i>Archiv der Pharmazie</i> 357, no. 1 (2024): e2300301. https://doi.org/10.1002/ardp.202300301.</p><p>These corrections are reflected in the updated <b>2D</b> Figure 1 and do not affect the scientific conclusions of the original manuscript. We apologize for the oversight and appreciate the opportunity to rectify these errors.</p>","PeriodicalId":128,"journal":{"name":"Archiv der Pharmazie","volume":"358 10","pages":""},"PeriodicalIF":3.6,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ardp.70120","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145237596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}